Addendum
Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18
Report documents
-
Addendum
Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18
Dossier assessment
Indication:
Moderate to severe rheumatoid arthritis in adult patients with insufficient response to prior treatment
Result of dossier assessment:
For patients ≤ 65 years with unfavourable prognosis pretreated once no hint of lesser benefit versus adalimumab. For 4 questions added benefit therefore not proven.
Additional information
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.
Project details
- Project no.
- A17-43
- Commission
- Commission awarded on 04.09.2017 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed